Medivir AB

MVR0

Company Profile

  • Business description

    Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

  • Contact

    Lunastigen 5
    PO Box 1086, 2nd floor
    Huddinge141 22
    SWE

    T: +46 854683100

    E: [email protected]

    https://www.medivir.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    10

Stocks News & Analysis

stocks

Investors overly negative on undervalued ASX share

Road to profitability is in sight as management continues to take the right steps.
stocks

Reporting season preview: February 2025

As of Wednesday, 24 companies under coverage have reported; you’ll find our analysis throughout this issue.
stocks

Signs of a turnaround for undervalued ASX share

Market likes the payoff from early efforts at reining in costs.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,811.9013.20-0.15%
CAC 408,186.387.840.10%
DAX 4022,715.25201.830.90%
Dow JONES (US)44,546.08165.35-0.37%
FTSE 1008,753.2520.790.24%
HKSE22,616.234.10-0.02%
NASDAQ20,026.7781.130.41%
Nikkei 22539,174.2524.820.06%
NZX 50 Index13,068.9379.750.61%
S&P 5006,114.630.44-0.01%
S&P/ASX 2008,537.1018.70-0.22%
SSE Composite Index3,355.839.110.27%

Market Movers